Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – The U.S. Food and Drug Administration approved the supplemental Biologics License
Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or
Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1670270816-0ad5575958954483983518d73656a96c.jpg "Should Military Members Open a Roth IRA?")